Korean J Radiol.  2017 Feb;18(1):54-70. 10.3348/kjr.2017.18.1.54.

Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful

Affiliations
  • 1Department of Imaging, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. akeraliya@partners.org
  • 2Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • 3Department of Nuclear Medicine and PET/CT, Jaslok Hospital and Research Centre, Mumbai 400026, India.

Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common histological subtype of Non-Hodgkin's lymphoma. As treatments continues to evolve, so do imaging strategies, and positron emission tomography (PET) has emerged as the most important imaging tool to guide oncologists in the diagnosis, staging, response assessment, relapse/recurrence detection,and therapeutic decision making of DLBCL. Other imaging modalities including magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, and conventional radiography are also used in the evaluation of lymphoma. MRI is useful for nervous system and musculoskeletal system involvement and is emerging as a radiation free alternative to PET/CT. This article provides a comprehensive review of both the functional and morphological imaging modalities, available in the management of DLBCL.

Keyword

Lymphoma; Diffuse large B cell lymphoma; FDG-positron emission tomography/CT; MRI

MeSH Terms

Female
Humans
Lymphoma, Large B-Cell, Diffuse/*diagnostic imaging/pathology/therapy
Magnetic Resonance Imaging/methods
Male
Multimodal Imaging/methods
Neoplasm Recurrence, Local
Positron Emission Tomography Computed Tomography/methods
Positron-Emission Tomography/methods
Precision Medicine/methods
Tomography, X-Ray Computed/methods
Full Text Links
  • KJR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr